Stonvex
Stonvex
StonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $42.56 | $40.00 | -6.02% | 1.0M |
| 05-11 | $39.43 | $36.32 | -7.89% | 1.0M |
| 05-12 | $36.69 | $36.58 | -0.30% | 0.5M |
| 05-13 | $36.67 | $35.26 | -3.85% | 0.4M |
| 05-14 | $35.18 | $36.15 | +2.76% | 0.5M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Fundamentals not available for PAHC.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.12B | $737.80M | $363.89M | $1.30B |
Operating Income | $146.24M | $101.59M | $51.26M | $110.47M |
Net Income | $78.01M | $53.99M | $26.53M | $48.26M |
EPS (Diluted) | $1.90 | $1.32 | $0.65 | $1.19 |
Total Assets | $1.45B | $1.41B | $1.39B | $1.36B |
Total Liabilities | $1.08B | $1.07B | $1.07B | $1.08B |
Cash & Equivalents | $54.93M | $55.49M | $72.77M | $68.04M |
Free Cash Flow OCF − CapEx | $4.64M | $3.75M | $-4.50M | $41.83M |
Shares Outstanding | 40.96M | 40.92M | 40.88M | 40.68M |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
No sell-side coverage available for PAHC.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.